Skip to content

BBNX BBNX EBITDA margin

EBITDA margin at other companies

Insulet logo
InsuletPODD
20.8%+1.5pp
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-6.4%-2.4pp
Medtronic logo
MedtronicMDT
25.9%-0.4pp
AdaptHealth logo
AdaptHealthAHCO
12.7%-5.9pp
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
60.2%+8.7pp

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Calculated from BBNX’s reported figures.

Based on trailing twelve months.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's EBITDA margin?
BBNX (BBNX) reported EBITDA margin of -68.4% in Q1 2026.
How has BBNX's EBITDA margin changed year-over-year?
BBNX's EBITDA margin increased by 10.3% year-over-year, from -76.3% to -68.4%.
What is the long-term trend for BBNX's EBITDA margin?
Over 2 years (2023 to 2025), BBNX's EBITDA margin has grown at a -50.8% compound annual growth rate (CAGR), from -288.7% to -69.9%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.